Tuberous Sclerosis Press Releases

Three recent studies show that the drug rapamycin reduces neurological symptoms in mouse models of tuberous sclerosis complex (TSC), a rare genetic disorder associated with epilepsy and autism. Scientists say those results could pave the way for effective treatment – and not just for TSC.

Three recent studies show that the drug rapamycin reduces neurological symptoms in mouse models of tuberous sclerosis complex (TSC), a rare genetic disorder associated with epilepsy and autism. Scientists say those results could pave the way for effective treatment – and not just for TSC.

The National Institute of Neurological Disorders and Stroke (NINDS) welcomes five new members to its National Advisory Neurological Disorders and Stroke Council. The Council serves as the principal advisory body to the NINDS, a component of the National Institutes of Health and the nation's primary supporter of basic, translational, and clinical research on the brain and nervous system.

Scientists have identified the second of two genes that cause tuberous sclerosis complex (TSC), a relatively common developmental disorder characterized by a number of abnormalities, including seizures, benign tumors in several organs, and variable emotional and cognitive disabilities. The discovery, to be reported in the August 8, 1997, issue of Science by David Kwiatkowski, M.D., Ph.D., and colleagues at Brigham and Women's Hospital in Boston, was funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Human Genome Research Institute (NHGRI), both components of the National Institutes of Health.

Scientists have identified the second of two genes that cause tuberous sclerosis complex (TSC), a relatively common developmental disorder characterized by a number of abnormalities, including seizures, benign tumors in several organs, and variable emotional and cognitive disabilities. The discovery, to be reported in the August 8, 1997, issue of Science by David Kwiatkowski, M.D., Ph.D., and colleagues at Brigham and Women's Hospital in Boston, was funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Human Genome Research Institute (NHGRI), both components of the National Institutes of Health.